Mylan NV (MYL)

MYL (NASDAQ:Drugs) EQUITY
$46.79
pos +0.00
+0.00%
Today's Range: 46.11 - 46.94 | MYL Avg Daily Volume: 4,681,200
Last Update: 07/29/16 - 4:00 PM EDT
Volume: 0
YTD Performance: -13.46%
Open: $0.00
Previous Close: $46.72
52 Week Range: $37.59 - $57.81
Oustanding Shares: 508,342,710
Market Cap: 23,749,771,411
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.00 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.54%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 29.20
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
29.20 27.40 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
12.18% -18.26% 41.36%
GROWTH 12 Mo 3 Yr CAGR
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
EBITDA 2.40B
Revenue 9.43B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.14 $1.57 $4.93 $5.92
Number of Analysts 8 7 7 7
High Estimate $1.20 $1.66 $5.05 $6.16
Low Estimate $1.04 $1.51 $4.85 $5.70
Prior Year $0.91 $1.43 $4.30 $4.93
Growth Rate (Year over Year) 25.14% 9.89% 14.55% 20.16%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
An investor should make good money on any turn in the drug maker's business or in investor sentiment.

Where Is the Insider Buying? Real Money Pro($)

The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen (BIIB) , Gilead Sciences (GILD) and Mylan (MYL) all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2% on the day.
Things are looking bullish.
"Papa's in the swing.He ain't too hip about that new breed babe.He ain't no drag.Papa's got a brand new bag."

Biotech Gets a Lifeline Real Money Pro($)

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.
It would take a rally and close back above $46 to alter the current bearish cast to the charts.

Avoid Valeant (Redux) Real Money Pro($)

-- The year-end financials that VRX filed on Friday disclosed a dangerously overleveraged balance sheet. Valeant has $30.3 billion in long-term debt, while goodwill totals $18.6 billion and 'intangibles' add up to $23.2 billion. In essence, the company paid up big time for a large amount of mergers and acquisitions -- and funded those transactions with a huge debt load. -- Valeant had $6 billion of book value at year's end, down $500 million from the prior quarter. Subtracting goodwill takes the company to $12.5 billion of negative book value. And if we 'guesstimate' that the value of VRX's intangible assets ultimately gets halved, the company's tangible net worth drops to  a negative $24 b
The ultimate value of the company's businesses (calculated by cash flows and profits) could be insufficient relative to its liabilities to provide any value at all. The year-end financials that VRX filed on Friday disclosed a dangerously overleveraged balance sheet. Valeant has $30.3 billion in long-term debt, while goodwill totals $18.6 billion and "intangibles" add up to $23.2 billion. In essence, the company paid up big time for a large amount of mergers and acquisitions -- and funded those transactions with a huge debt load. Valeant had $6 billion of book value at year's end, down $500 million from the prior quarter. Subtracting goodwill takes the company to $12.5 billion of negative book value. And if we "guesstimate" that the value of VRX's intangible assets ultimately gets halved, the company's tangible net worth drops to  a negative $24 billion. Combined with Valeant's $30 billion of debt, that translates into a distressed and foundering company. VRX said its $30.5 billion of intangible assets represen
Valeant delighted shareholders Monday with news that Perrigo's Joseph Papa is getting into the driver's seat. 
Other companies have suffered following the debacle.

Columnist Conversations

Market continues to be mixed.  Oil having a rare up day of late, but still up less than 1% on day.  ...
My colleague Suz Smith (RM contributor) often talk about different trade scenarios and structures, importantly...
Thursday's Philadelphia Inquirer reported that the average requested increase for individual health insurance ...
Markets set to open slightly lower as second quarter GDP comes in at a much lower than expected 1.2% and first...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.